This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ReNeuron Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

ReNeuron Group has a total shareholder equity of £2.4M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £6.4M and £4.0M respectively.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£5.08m
Eşitlik	UK£2.42m
Toplam yükümlülükler	UK£4.00m
Toplam varlıklar	UK£6.42m

Son finansal sağlık güncellemeleri

Recent updates

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Jul 15

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Jan 22

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Oct 12

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

Jun 04

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

Jan 12

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

Nov 20

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RENE's short term assets (£5.7M) exceed its short term liabilities (£3.8M).

Uzun Vadeli Yükümlülükler: RENE's short term assets (£5.7M) exceed its long term liabilities (£189.0K).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RENE is debt free.

Borcun Azaltılması: RENE has not had any debt for past 5 years.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RENE has less than a year of cash runway based on its current free cash flow.

Tahmini Nakit Akışı: RENE has less than a year of cash runway if free cash flow continues to grow at historical rates of 16% each year.

This company listing is no longer active

ReNeuron Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

Recent updates

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

Consensus EPS estimates upgraded to UK£0.10 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Consensus forecasts updated

First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

ReNeuron Group plc Appoints John Hawkins as Chief Financial Officer

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Price target decreased to UK£2.22

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022

Price target decreased to UK£2.19

ReNeuron Group plc, Annual General Meeting, Jul 14, 2022

Price target decreased to UK£2.04

ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022

ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Price target decreased to UK£2.04

First half 2022 earnings: EPS and revenues miss analyst expectations

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

New 90-day high: UK£1.11

New 90-day low: UK£0.72

First half 2021 earnings released: UK£0.22 loss per share

New 90-day low: UK£0.78

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020

New 90-day low: UK£0.85

Analysts update estimates

ReNeuron Group plc Auditor Raises 'Going Concern' Doubt

Full year earnings released - UK£0.36 loss per share

New 90-day low - UK£1.08

New 90-day low - UK£1.22

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin